Capecitabine in advanced hepatocellular carcinoma

Digestive and Liver Disease

Volumn 48, Issue 10, 2016, Pages 1260-1261

  Murer, Francesca ^a   Pozzan, Caterina ^a   Peserico, Giulia ^a   Farinati, Fabio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; REGORAFENIB; SORAFENIB; ANTINEOPLASTIC ANTIMETABOLITE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL TRIAL; HUMAN; LETTER; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SURVIVAL ANALYSIS;

EID: 84979730481     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.06.037     Document Type: Letter

References (5)

1. [1] Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359 (2008), 378–390.
2. [2] Ann-Lii, C., Yoon-Koo, K., Zhendong, C., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 10 (2009), 25–34.
3. [3] Granito, A., Marinelli, S., Terzi, E., et al. Metronomic capecitabine as second-line treatment in heaptocellular carcinoma after sorafenib failure. Digestive and Liver Disease 47 (2015), 518–522.
4. [4] Ge, S., Huang, D., Systemic therapies for hepatocellular carcinoma. Drug Discoveries & Therapeutics 9 (2015), 352–362.
5. [5] Marin, J.J.G., Romero, M.R., Briz, O., Molecular bases of liver cancer refractoriness to pharmacological treatment. Current Medicinal Chemistry 17 (2010), 709–740.